Amestejani Morteza, Salehi Bahareh Seyed, Vasigh Mostafa, Sobhkhiz Azadeh, Karami Mehdi, Alinia Hossein, Kamrava Seyed Kamran, Shamspour Navab, Ghalehbaghi Babak, Behzadi Ashkan Heshmatzade
Orumieh University of Medical Science, Orumieh, Iran.
J Drugs Dermatol. 2012 Mar;11(3):327-30.
The role of vitamin D in Atopic Dermatitis (AD) is ambiguous and clinical trials are needed to assess the role of vitamin D in the treatment of AD. The aim of this clinical trial study to evaluate the effect of vitamin D supplementation on patients with AD.
sixty AD patients were included in a randomized, double-blind, placebo-controlled trial study. They were randomly divided into two groups and treated for 60 days: group vitamin D (n=30), and placebo group (n=30). The two groups were as follows: Group D, 1600 IU cholecalciferol (vitamin D) and second group placebo. The severity of AD was evaluated based on SCORAD (Scoring Atopic Dermatitis) and TIS (Three Item Severity score) value by the same trained physician before and after the trial.
According to SCORAD and TIS value index in the vitamin D group showed significant improvement in patients with mild, moderate and severe AD (P<0.05) and in patients who the intake placebo, this improvement didn't showed (P>0.05).
Results mention that supplementation with oral vitamin D dramatically improved disease severity in AD patients.
维生素D在特应性皮炎（AD）中的作用尚不明确，需要进行临床试验来评估维生素D在AD治疗中的作用。本临床试验研究旨在评估补充维生素D对AD患者的影响。
60例AD患者纳入一项随机、双盲、安慰剂对照试验研究。他们被随机分为两组，治疗60天：维生素D组（n = 30）和安慰剂组（n = 30）。两组情况如下：D组，1600 IU胆钙化醇（维生素D），第二组为安慰剂。在试验前后，由同一位经过培训的医生根据SCORAD（特应性皮炎评分）和TIS（三项严重程度评分）值评估AD的严重程度。
根据SCORAD和TIS值指数，维生素D组中轻度、中度和重度AD患者均有显著改善（P < 0.05），而服用安慰剂的患者未出现这种改善（P > 0.05）。
结果表明，口服补充维生素D可显著改善AD患者的疾病严重程度。
